JBM (Healthcare) Limited provided consolidated earnings guidance for the six months ended 30 September 2021. the Group's profit attributable to equity shareholders of the Company for the six months ended 30 September 2021 (the "Review Period") is expected to decrease by more than 50% as compared to that of approximately HKD 21,650,000 for the corresponding period in 2020 (the "Previous Period"). This decrease was mainly attributable to the sluggish consumer demand in both domestic and certain overseas markets caused by the COVID-19 pandemic. The lingering travel restrictions across the region have had a negative impact on the sales and selling prices of certain products of the Group. Furthermore, there was an one-off pandemic relief subsidy in the amount of approximately HKD 6.3 million from the government of the Hong Kong Special Administrative Region (the "Hong Kong Government") during the Previous Period.